Improvement in Body Surface Area is Associated with Better Quality of Life Among Patients with Psoriasis in the Corrona Psoriasis Registry

Background: Vitiligo is a common, acquired, mucocutaneous discoloration characterized by well-circumscribed depigmented macules. It has profound potential for cosmetic disfigurement and social stigma, which is an often neglected aspect of the disease. Objectives: To analyze the impact of vitiligo on the quality of life (Qol) of patients in western India and To determine the contributory factors. Methods: A cross-sectional, observational study was conducted at a tertiary care hospital on 60 patients with vitiligo (were enrolled after informed consent and ethical approval). Basic patient-related (age, gender, socioeconomic status, co-morbidities) and vitiligo-related variables (body surface area involved, stability, duration of disease, treatment modality) were noted. This information were collated with QoL using a standardized questionnaire, the Dermatology Life Quality Index (DLQI). Statistical analysis was performed using Spearman’s rank correlation coefficient, Pearson’s r, unpaired t-test (SPSS version 16). Results: Mean DLQI score of the study sample was 3.15 ± 4.2 (small effect on QoL). The mean DLQI score in females (3.97) was significantly higher than in males (1.92) (P = 0.046). Also, the DLQI demonstrated a significant positive correlation with body surface area involvement (Spearman’s correlation coefficient = 0.306) (P = 0.018). Other factors were not found to affect the DLQI. Conclusions: Various modifiable and non-modifiable factors influence the QoL of vitiligo patients. Gender- associated stigma may be alleviated by counseling and creating awareness, while the body surface area involvement may be addressed by instituting and appropriate treatment. The clinician must be vigilant for any subtle signs of impairment of QoL to enable timely intervention.

Download Full-text

27611 Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.637 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB156

Author(s):

Linda Stein Gold ◽

Edward Lain ◽

Jerry Bagel ◽

Abby Jacobson

Keyword(s):

Quality Of Life ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Poor Quality

Download Full-text

P14 Reducing medication errors using prescribing nudges: intravenous aciclovir on paediatric intensive care

Archives of Disease in Childhood ◽

10.1136/archdischild-2020-nppg.23 ◽

2020 ◽

Vol 105 (9) ◽

pp. e13.1-e13

Author(s):

Jenny Gray ◽

Nicholas Jones ◽

Olivia Fuller ◽

Andrew Schia

Keyword(s):

Intensive Care ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Error Rate ◽

Paediatric Intensive Care ◽

Electronic Prescribing ◽

Second Phase ◽

Quality Of Prescribing

AimThis Quality Improvement project is the second phase of a long term project to improve the quality of prescribing on the paediatric intensive care unit (PICU). Small adjustments are made to the electronic prescribing (EP) system, known as ‘nudges’, with the aim of improving the quality of prescribing in terms of error rate or user experience.1 2Intravenous aciclovir is prescribed to most patients admitted to the PICU with suspected meningitis/encephalitis. There is a complicated dosing schedule where the prescriber must decide whether to use body surface area (BSA) or weight to calculate the required dose. Underdosing risks subtherapeutic treatment of a viral encephalitis and overdosing risks acute kidney injury. Within our EP system, dosing by weight can be automated, but dosing by BSA cannot.A project in 2018 used a ‘nudge’ to alter the order of prescribing options in the drop down menu on the EP system. This reduced the error rate from 26% to 17% by reducing the likelihood of picking the wrong indication for acyclovir.3 However, a re-audit in October to December 2018 found the error rate had crept back up to 32%. Prescribing on the EP system is a multi-step process. Prescribers had to pick ‘aciclovir’ to choose the weight based dose or ‘aciclovir injection 3 month-11 yr‘ to choose the BSA based dosing. When ‘aciclovir’ was picked, this removed the body surface area dosing option from the prescriber’s screen and led them in the direction of an incorrect dose.MethodThe intervention for this project was to amalgamate all weight and BSA dosing options for acyclovir within the EP system, and then order them by age so that the prescriber could see all options simultaneously. This change was designed and implemented by our electronic prescribing support pharmacist in April 2019. Pre and post change prescriptions were audited by pharmacy undergraduate students for accuracy using data downloaded from the EP system.ResultsThe error rate post change was 8% (pre change 32%). The remaining errors reflect transcribing of an incorrect dose initiated outside of the PICU from a referring ward or hospital.ConclusionThis project shows that small, ‘smart’ changes within EP configuration can improve the quality of prescribing.Future work involves working with the software company to incorporate the ability to automatically calculate the dose based on BSA, further reducing the need for manual calculations. This project would not have been possible without the skills and knowledge of our electronic prescribing support pharmacy team.ReferencesPatel MS, et al. Nudge units to improve the delivery of health care. NEJM 2018; 378: 214–216Cafazzo JA, et al. From discovery to design: the evolution of human factors in healthcare. healthcare quarterly 2012; 15: 24–29Gunning C, Gray J. Audit of acyclovir prescribing to assess whether changing the order of drop down box options in an electronic prescribing system can reduce prescribing errors. Archives of Disease in Childhood 2019; 104:7

Download Full-text

The distance from the Amplatzer septal occluder to the mitral valve in patients undergoing interventional closure of defects in the oval fossa increases with growth of the patient

Cardiology in the Young ◽

10.1017/s1047951104005050 ◽

2004 ◽

Vol 14 (5) ◽

pp. 494-497 ◽

Cited By ~ 4

Author(s):

Robert F. English ◽

Jose A. Ettedgui

Keyword(s):

Mitral Valve ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Left Atrial ◽

Left Ventricular ◽

Amplatzer Septal Occluder ◽

Operative Closure

The Amplatzer septal occluder is an alternative to operative closure of atrial septal defects within the oval fossa. An issue when deploying the device is its distance from the mitral valve. The purpose of this study is to determine how this distance changes with growth of the patient. We identified, through a review of charts, all patients undergoing closure of defects within the oval fossa by insertion of an Amplatzer septal occluder. Data were obtained from the echocardiogram 24 hours after closure, and at most recent follow-up, including left ventricular end-diastolic diameter, left atrial diameter, degree of mitral valvar regurgitation, body surface area, and distance from the device to the mitral valve. We divided the patients into 2 groups based upon change in body surface area. The first group had an increase in body surface area of at least 10%. All others were in the second group.We inserted 55 Amplatzer septal occluders in 54 patients. Of these we excluded 17 patients, 1 because quality of images was inadequate, 1 who underwent placement of 2 devices, 1 in whom the device embolised to the left ventricle the day after deployment, and 14 who have not yet had a follow-up echocardiogram.The group which exhibited an increase in body surface area of greater than 10% demonstrated an increase in distance from the device to the mitral valve, left ventricular end-diastolic, and left atrial diameters. Those who did not undergo significant growth had no increase in distance from the device to the mitral valve, but did have an increase in left atrial and left ventricular end-diastolic diameters. No patient developed mitral regurgitation. We conclude that, when deploying an Amplatzer septal occluder close to the mitral valve in children, the distance from the device to the mitral valve can be expected to increase with growth of the patient.

Download Full-text

Differences in pressure sensitivity and tactile discrimination among individuals as a function of gender and body surface area

PsycEXTRA Dataset ◽

10.1037/e527352012-548 ◽

2006 ◽

Author(s):

Somer M. Givens ◽

David B. Boles

Keyword(s):

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Pressure Sensitivity ◽

Tactile Discrimination

Download Full-text

Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism

Thrombosis and Haemostasis ◽

10.1055/s-0038-1650643 ◽

1996 ◽

Vol 76 (05) ◽

pp. 682-688 ◽

Cited By ~ 33

Author(s):

Jos P J Wester ◽

Harold W de Valk ◽

Karel H Nieuwenhuis ◽

Catherine B Brouwer ◽

Yolanda van der Graaf ◽

...

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Small Body ◽

Bleeding Risk ◽

Risk Scores ◽

Risk Of Bleeding ◽

Acute Venous Thromboembolism

Summary Objective: Identification of risk factors for bleeding and prospective evaluation of two bleeding risk scores in the treatment of acute venous thromboembolism. Design: Secondary analysis of a prospective, randomized, assessor-blind, multicenter clinical trial. Setting: One university and 2 regional teaching hospitals. Patients: 188 patients treated with heparin or danaparoid for acute venous thromboembolism. Measurements: The presenting clinical features, the doses of the drugs, and the anticoagulant responses were analyzed using univariate and multivariate logistic regression analysis in order to evaluate prognostic factors for bleeding. In addition, the recently developed Utrecht bleeding risk score and Landefeld bleeding risk index were evaluated prospectively. Results: Major bleeding occurred in 4 patients (2.1%) and minor bleeding in 101 patients (53.7%). For all (major and minor combined) bleeding, body surface area ≤2 m2 (odds ratio 2.3, 95% Cl 1.2-4.4; p = 0.01), and malignancy (odds ratio 2.4, 95% Cl 1.1-4.9; p = 0.02) were confirmed to be independent risk factors. An increased treatment-related risk of bleeding was observed in patients treated with high doses of heparin, independent of the concomitant activated partial thromboplastin time ratios. Both bleeding risk scores had low diagnostic value for bleeding in this sample of mainly minor bleeders. Conclusions: A small body surface area and malignancy were associated with a higher frequency of bleeding. The bleeding risk scores merely offer the clinician a general estimation of the risk of bleeding. In patients with a small body surface area or in patients with malignancy, it may be of interest to study whether limited dose reduction of the anticoagulant drug may cause less bleeding without affecting efficacy.

Download Full-text

The use of Body Surface Index as a Better Clinical Health indicators Compare to Body Mass Index and Body Surface Area for Clinical Application

International Journal of Scientific Research in Science Engineering and Technology ◽

10.32628/ijsrset2184117 ◽

2018 ◽

pp. 131-136

Author(s):

Shirazu I. ◽

Theophilus. A. Sackey ◽

Elvis K. Tiburu ◽

Mensah Y. B. ◽

Forson A.

Keyword(s):

Surface Area ◽

Body Surface Area ◽

Clinical Application ◽

Body Surface ◽

Body Height ◽

Health Indicators ◽

The Body ◽

Body Parameters ◽

The Relationship ◽

Individual Body

The relationship between body height and body weight has been described by using various terms. Notable among them is the body mass index, body surface area, body shape index and body surface index. In clinical setting the first descriptive parameter is the BMI scale, which provides information about whether an individual body weight is proportionate to the body height. Since the development of BMI, two other body parameters have been developed in an attempt to determine the relationship between body height and weight. These are the body surface area (BSA) and body surface index (BSI). Generally, these body parameters are described as clinical health indicators that described how healthy an individual body response to the other internal organs. The aim of the study is to discuss the use of BSI as a better clinical health indicator for preclinical assessment of body-organ/tissue relationship. Hence organ health condition as against other body composition. In addition the study is `also to determine the best body parameter the best predict other parameters for clinical application. The model parameters are presented as; modeled height and weight; modelled BSI and BSA, BSI and BMI and modeled BSA and BMI. The models are presented as clinical application software for comfortable working process and designed as GUI and CAD for use in clinical application.

Download Full-text

An investigation into the age and developmental stage related association between plasma concentrations of leptin and growth hormone, linear growth velocity, body mass index and body surface area in boys between the ages of 1 and 20 years

Endocrine Abstracts ◽

10.1530/endoabs.70.aep850 ◽

2020 ◽

Author(s):

Naseem Afzaal Ahmed ◽

Mazhar Qayyum ◽

Maleeha Akram ◽

Fahim Tahir ◽

Kiran Afshan ◽

...

Keyword(s):

Body Mass Index ◽

Growth Hormone ◽

Developmental Stage ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Growth Velocity ◽

Linear Growth ◽

Plasma Concentrations ◽

Related Association

Download Full-text

Oxygen Fraction Adjustment According to Body Surface Area during Extracorporeal Circulation

The Heart Surgery Forum ◽

10.1532/hsf.1325 ◽

2015 ◽

Vol 18 (3) ◽

pp. 098

Author(s):

Cem Arıtürk ◽

Serpil Ustalar Özgen ◽

Behiç Danışan ◽

Hasan Karabulut ◽

Fevzi Toraman

Keyword(s):

Body Temperature ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Extracorporeal Circulation ◽

Group Iii ◽

Oxygen Fraction ◽

Arterial Blood ◽

Group I ◽

Group Ii

Background: The inspiratory oxygen fraction (FiO2) is usually set between 60% and 100% during conventional extracorporeal circulation (ECC). However, this strategy causes partial oxygen pressure (PaO2) to reach hyperoxemic levels (>180 mmHg). During anesthetic management of cardiothoracic surgery it is important to keep PaO2 levels between 80-180 mmHg. The aim of this study was to assess whether adjusting FiO2 levels in accordance with body temperature and body surface area (BSA) during ECC is an effective method for maintaining normoxemic PaO2 during cardiac surgery.Methods: After approval from the Ethics Committee of the University of Acıbadem, informed consent was given from 60 patients. FiO2 adjustment strategies applied to the patients in the groups were as follows: FiO2 levels were set as 0.21 × BSA during hypothermia and 0.21 × BSA + 10 during rewarming in Group I; 0.18 × BSA during hypothermia and 0.18 × BSA + 15 during rewarming in Group II; and 0.18 × BSA during hypothermia and variable with body temperature during rewarming in Group III. Arterial blood gas values and hemodynamic parameters were recorded before ECC (T1); at the 10th minute of cross clamp (T2); when the esophageal temperature (OT) reached 34°C (T3); when OT reached 36°C (T4); and just before the cessation of ECC (T5).Results: Mean PaO2 was significantly higher in Group I than in Group II at T2 and T3 (P = .0001 and P = .0001, respectively); in Group I than in Group III at T1 (P = .02); and in Group II than in Group III at T2, T3, and T4 (P = .0001 for all). Conclusion: Adjustment of FiO2 according to BSA rather than keeping it at a constant level is more appropriate for keeping PaO2 between safe level limits. However, since oxygen consumption of cells vary with body temperature, it would be appropriate to set FiO2 levels in concordance with the body temperature in the rewarming period.

Download Full-text